KALARIS THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
KALARIS THERAPEUTICS, INC. (KLRS) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 3.52% for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-07.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2025-03-07
- KALARIS THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2023-09-30 was 4.01%, a 38.75% increase year-over-year.
- KALARIS THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2023-06-30 was 3.61%, a 33.70% increase year-over-year.
- KALARIS THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2023-03-31 was 3.46%, a 100.00% increase year-over-year.
- KALARIS THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2022-09-30 was 2.89%, a 197.94% increase year-over-year.
- KALARIS THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 3.52%, a 76.00% increase from fiscal 2022.
- KALARIS THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 2.00%, a 129.89% increase from fiscal 2021.
- KALARIS THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2021 was 0.87%, a 141.67% increase from fiscal 2020.
- KALARIS THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2020 was 0.36%, a 78.18% decline from fiscal 2019.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|
| 2023-12-31 | 3.52% 10-K · filed 2025-03-07 | |||
| 2023-09-30 | 4.01% 10-Q · filed 2023-11-02 | 3.51% 10-Q · filed 2023-11-02 | ||
| 2023-06-30 | 3.61% 10-Q · filed 2023-08-03 | 3.46% 10-Q · filed 2023-08-03 | ||
| 2023-03-31 | 3.46% 10-Q · filed 2024-05-13 | |||
| 2022-12-31 | 2.00% 10-K · filed 2024-03-15 | |||
| 2022-09-30 | 2.89% 10-Q · filed 2022-11-03 | 2.16% 10-Q · filed 2022-11-03 | ||
| 2022-06-30 | 2.70% 10-Q · filed 2022-08-04 | 1.95% 10-Q · filed 2022-08-04 | ||
| 2022-03-31 | 1.73% 10-Q · filed 2023-05-04 | |||
| 2021-12-31 | 0.87% 10-K · filed 2023-02-15 | |||
| 2021-09-30 | 0.97% 10-Q · filed 2021-11-05 | 0.84% 10-Q · filed 2021-11-05 | ||
| 2021-06-30 | 1.07% 10-Q · filed 2021-08-06 | 0.83% 10-Q · filed 2021-08-06 | ||
| 2021-03-31 | 0.64% 10-Q · filed 2021-05-06 | |||
| 2020-12-31 | 0.36% 10-K · filed 2022-02-10 | |||
| 2020-09-30 | 0.35% 10-Q · filed 2020-11-10 | 0.35% 10-Q · filed 2020-11-10 | ||
| 2020-06-30 | 0.48% 10-Q · filed 2020-09-02 | |||
| 2019-12-31 | 1.65% 10-K · filed 2021-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |